跳至主要内容
临床试验/NCT07039539
NCT07039539尚未招募不适用

Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial

University of Sao Paulo2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2026年8月1日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
32
试验地点
2
主要终点
Modulation of drug use

研究概览

简要总结

This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS. As secondary objectives, the study will investigate the intervention's effect on health parameters (i.e., blood), quality of life, sleep quality, body image, eating behavior, depression, anxiety, fatigue, aggressiveness, cardiovascular parameters, muscle strength, body composition and muscle cross-sectional area outcomes.

详细描述

  1. Scientific Context and Rationale:

The abusive use of anabolic-androgenic steroids (AAS) for aesthetic and physical performance enhancing purposes (i.e., non-clinical) is a global problem that negatively affects the health of men and women of various age groups. In fact, the World Drug Report reinforced the concern about the non-clinical use of these drugs (World Drug Report, 2023). It is estimated that the global prevalence of AAS use is 6.4% and 1.6% among physically active men and women (Sagoe et al., 2014), respectively, and can reach 30% in bodybuilding gyms (Abrahin et al., 2014).

In short, AAS are synthetic substances similar to the hormone testosterone and are part of the list of performance and image enhancing drugs (PIED). The AAS promotes androgenic effects, such as spermatogenesis, deepening of the voice, increased libido, and changes in mood, along with anabolic effects, such as greater synthesis and lower protein degradation, and increased lipolytic activity. However, the abusive and prolonged use of AAS can negatively affect several health parameters. For example, AAS users are more prone to arrhythmias and sudden death, elevated mean arterial pressure over 24 hours, increases in the amount of calcium in the coronary arteries, and volume of atheromatous plaques (Baggish et al., 2017) . Additionally, the use of high concentrations of AAS (i.e., ≥ 200 mg per week) is associated with decreased endogenous testosterone production, spermatogenesis, and gonadal atrophy (Nieschlag & Vorona, 2015). The seriousness of this global problem is aggravated when we consider that 32% of abusive users develop addiction (Pope, Kanayama, et al., 2014).

It is important to emphasize that the investigation of the effects of AAS abuse in health parameters is not methodologically trivial. The conduct of randomized and controlled studies is not possible because the obvious ethical impossibility of prescribing such substances to healthy humans, especially in the use schemes that are seen in the real world, which combine several drugs (a technique known as polypharmacy) in supraphysiological doses and in a chronic manner. In addition, as described, the use of AAS affects several systems in the human body, which requires a multidisciplinary evaluative approach. As a result, the current evidence on the damage caused to health by AAS is mostly of low scientific quality, and comes from cross-sectional studies, retrospectives, case studies, and opinion articles. Together, the conduction of better quality studies are needed in order to increase understanding about harm reduction strategies for abusive users. In this scenario, prospective cohort studies involving individuals planning to self-conduct the use of AAS emerge as an ethically viable and methodologically appropriate option for investigating the topic. (Bonnecaze et al., 2021; Rops et al., 2022)

Despite the advances achieved by prospective cohort studies with habitual users of AAS, several gaps remain regarding the development of harm reduction interventions in this population. Briefly, the harm reduction strategy aims to decrease and/or cease the use of AAS in the long term. However, it is worth noting that ceasing the use of these drugs is extremely complex, as most users are affected by post-use withdrawal syndrome, which is characterized by symptoms of depression, a sharp drop in libido, and anhedonia, which stimulates the continuous and recurrent use of AAS. Therefore, harm reduction also aims to guide the user to (i) reduce the frequency and dose of AAS, (ii) minimize health complications due to the misuse of additional substances and/or contaminated material, and (iii) provide specialized multidisciplinary support for long-term monitoring of health parameters. Thus, controlled clinical trials aimed at evaluating new strategies to minimize the harm caused by the abusive use of AAS are urgent (Anawalt , 2019; Bonnecaze et al., 2021; Pope, Wood, et al., 2014). 2. Study Justification and Objective:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None (Outcomes Assessor)

盲法说明

The researcher responsible for performing interviews will be blinded to the allocation of groups.

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Anyone over 15 years of age;
  • Planning to use/increase the dose of AAS for aesthetic and/or physical performance purposes;
  • Plan to use/increase the dose of AAS during eight to twelve weeks.

排除标准

  • Medical prescription for AAS use;
  • Use for sexual reassignment.

研究组 & 干预措施

Harm reduction group (HR)

Experimental

Participants will undergo health exams and complete the research questionnaires at time points T0, T0.5, T1 and T2. Additionally, every 15 days between T0 and T1, the harm reduction intervention will attend 30 minutes long counseling sessions with the research team. These brief counseling sessions are based on a technique known as "Brief Intervention", which focuses on the participant's needs and discussion of health exams results.

干预措施: harm reduction intervention in non-clinical anabolic-androgenic steroids users (Behavioral)

Control group (CTRL)

No Intervention

Participants will undergo health exams at specific time points: T0 (before the start of the anabolic-androgenic steroids cycle), T0.5 (4 weeks into the cycle), and T1 (8 weeks into the cycle) and T2 (one year after T1).

结局指标

主要结局

Modulation of drug use

时间窗: 2 months

reduction in the total volume of drugs planned for the cycle compared to that used after the intervention (measured in milligrams of drugs)

次要结局

  • Short-term and long-term effects on cumulative use of anabolic-androgenic on body image(Eight weeks after AAS cycle's onset and one year after the end of the AAS cycle.)
  • Short-term and long-term effects on cumulative use of anabolic-androgenic on eating behavior(Eight weeks after AAS cycle's onset and one year after the end of the AAS cycle.)
  • Decision-changing factors(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Bruno Gualano

President of the Center for Lifestyle Medicine - School of Medicine of University of São Paulo

University of Sao Paulo

研究点 (2)

Loading locations...

相似试验